Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response To Atezolizumab In Phase 2 Clinical Trial; Results Published In Peer-Reviewed Journal, Clinical Cancer Research
Portfolio Pulse from Benzinga Newsdesk
Oncocyte Corp. announced positive results for its DetermaIO assay, which predicts response to atezolizumab in breast cancer patients. The study, published in Clinical Cancer Research, shows DetermaIO's potential in the oncology diagnostics market.
October 08, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncocyte's DetermaIO assay demonstrated significant predictive power in a Phase 2 trial for breast cancer treatment with atezolizumab, potentially boosting its market position in oncology diagnostics.
The publication of positive results for DetermaIO in a peer-reviewed journal validates its utility in predicting treatment response, which could enhance Oncocyte's market position and drive stock price upward. The assay's success in a multi-billion-dollar market is a significant development.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100